Bartlett John D, Miller Kevin M
David Geffen School of Medicine at University of California Los Angeles, Stein Eye Institute, Los Angeles, California, USA.
Curr Opin Ophthalmol. 2016 Jan;27(1):76-81. doi: 10.1097/ICU.0000000000000219.
Femtosecond lasers for use during cataract surgery carry significant purchase and use costs. The aim of this article is to help surgeons and surgery centers anticipate financial issues related to implementing femtosecond laser-assisted cataract surgery (FLACS). Such scenarios hopefully can help to inform decision making around the purchase and use of these lasers.
FLACS has several potential advantages over traditional phacoemulsification. However, although studies have demonstrated noninferiority of FLACS, there continues to be few data to support significantly improved visual outcomes. The literature does show a significantly higher cost for FLACS. As this cost can be passed on to patients under Medicare rules, there is the potential for increased physician revenue, which can be a motivator for adoption of this new technology. The magnitude of this increase is heavily influenced by the financial details of the implementation, like the cost of the laser, the volume of surgery performed, and the incremental increase in revenue.
A financial analysis should be performed prior to purchasing a femtosecond laser. This analysis can help predict if FLACS is going to be a financial windfall or a money loser.
白内障手术中使用的飞秒激光购置和使用成本高昂。本文旨在帮助外科医生和手术中心预测与实施飞秒激光辅助白内障手术(FLACS)相关的财务问题。此类情况有望为围绕这些激光的购置和使用决策提供参考。
与传统超声乳化白内障吸除术相比,FLACS具有若干潜在优势。然而,尽管研究已证明FLACS并不逊色,但仍缺乏足够数据支持其能显著改善视觉效果。文献显示FLACS的成本显著更高。由于根据医疗保险规则,这笔费用可转嫁给患者,因此医生收入有可能增加,这可能成为采用这项新技术的一个动力。收入增加的幅度在很大程度上受实施的财务细节影响,如激光成本、手术量以及收入的增量增长。
在购买飞秒激光之前应进行财务分析。该分析有助于预测FLACS会带来财务收益还是亏损。